Study to Investigate the Absolute Bioavailability of Oral Sylibin

Phase 1 Completed 8 enrolled Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Fundación Mutua Madrileña · collab

RandomizedCrossoverOpen-labelTreatment

Summary

This clinical trial phase I in healthy volunteers is intended to describe the oral bioavailability of the silybin-phosphatidylcholine complex by calculating the area under the curve (AUC0-? and AUC0-12) after administration of the same dose of oral silybin (AUCo) and intravenous silybin (AUC iv).

Timeline

Start: 2013-10
Primary completion: 2013-11
Completion: 2014-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	silybin phosphatidylcholine	Unknown	360 mg	Oral
Comparator	sylibin	Unknown	350 mg	Intravenous

Indications

No indication recorded.